Granulocyte colony-stimulating factor: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Granulocyte colony-stimulating factor (G-CSF)''' is a glycoprotein of MW 25 kDa, which stimulate the production of [[neutrophil]]s and their precursors, and is used to treat [[neutropenia]]. | '''Granulocyte colony-stimulating factor (G-CSF)''', is a glycoprotein of MW 25 kDa, which stimulate the production of [[neutrophil]]s and their precursors, and is used to treat [[neutropenia]]. There are two forms used in treatment, '''filgrastim''' (Neupogen in the U.S.) and '''pegfilgastrim'''. | ||
It is a [[glycoprotein]] containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.<ref>{{MeSH}}</ref> | It is a [[glycoprotein]] containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.<ref>{{MeSH}}</ref> It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF), which was removed from the U.S. market in 2008.<ref name=Guide>{{citation | ||
| author = Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff A | |||
It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF), the | | title = 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | ||
| journal = J Clin Oncol | |||
| date = 2006 Jul 1| volume = 24 | issue = 19 | pages = 3187-205 | |||
| url =http://guideline.gov/content.aspx?id=9419 }}</ref> | |||
==Medical indications== | ==Medical indications== | ||
Labeled as approved uses by the U.S. [[Food and Drug Administration]]:<ref>{{citation | '''Labeled as approved uses''' by the U.S. [[Food and Drug Administration]]:<ref>{{citation | ||
| url = http://www.medscape.com/druginfo/dosage?cid=med&drugid=9370&drugname=Neupogen+Inj&monotype=default | | url = http://www.medscape.com/druginfo/dosage?cid=med&drugid=9370&drugname=Neupogen+Inj&monotype=default | ||
| title = Neupogen Inj: Doses and Indications | | title = Neupogen Inj: Doses and Indications | ||
| publisher = American Society for Health System Pharmacists/Medscape}}</ref> Chemotherapy-induced neutropenia, [[congenital neutropenia]], [[cyclic neutropenia]], [[idiopathic neutropenia]], [[ | | publisher = American Society for Health System Pharmacists/Medscape}}</ref> Chemotherapy-induced neutropenia, [[congenital neutropenia]], [[cyclic neutropenia]], [[idiopathic neutropenia]], neutropenia secondary to [[acute myeloid leukemia]] treatment]], prevention of neutropenia from cancer chemotherapy, mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis, [[severe chronic neutropenia]] | ||
Unlabeled | '''Unlabeled uses''': [[AIDS-associated neutropenia]], [[drug-induced neutropenia]], [[myelodysplastic syndrome]], [[myeloid engraftment enhancement]] | ||
==Experimental use== | |||
As a synergistic combination with [[erythropoetin]], it has been used, in tissue culture and in rats, to accelerate mechanisms of repair associated with [[stroke]] and [[peripheral ischemia]].<ref>{{citation | |||
| title = Granulocyte Colony-Stimulating Factor Activating HIF-1α Acts Synergistically with Erythropoietin to Promote Tissue Plasticity | |||
| url = http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0010093 | |||
| journal = PLoS ONE | volume = 5 |issue = 4: e10093| doi=10.1371/journal.pone.0010093 | |||
| year =2010 | |||
| author = Liu S-P, Lee S-D, Lee H-T, Liu DD, Wang H-J, ''et al''. }}</ref> | |||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
Latest revision as of 15:48, 30 July 2010
Granulocyte colony-stimulating factor (G-CSF), is a glycoprotein of MW 25 kDa, which stimulate the production of neutrophils and their precursors, and is used to treat neutropenia. There are two forms used in treatment, filgrastim (Neupogen in the U.S.) and pegfilgastrim.
It is a glycoprotein containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.[1] It is not the same agent as granulocyte-macrophage colony-stimulating factor (GM-CSF), which was removed from the U.S. market in 2008.[2]
Medical indications
Labeled as approved uses by the U.S. Food and Drug Administration:[3] Chemotherapy-induced neutropenia, congenital neutropenia, cyclic neutropenia, idiopathic neutropenia, neutropenia secondary to acute myeloid leukemia treatment]], prevention of neutropenia from cancer chemotherapy, mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis, severe chronic neutropenia
Unlabeled uses: AIDS-associated neutropenia, drug-induced neutropenia, myelodysplastic syndrome, myeloid engraftment enhancement
Experimental use
As a synergistic combination with erythropoetin, it has been used, in tissue culture and in rats, to accelerate mechanisms of repair associated with stroke and peripheral ischemia.[4]
References
- ↑ Anonymous (2024), Granulocyte colony-stimulating factor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff A (2006 Jul 1), "2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline", J Clin Oncol 24 (19): 3187-205
- ↑ Neupogen Inj: Doses and Indications, American Society for Health System Pharmacists/Medscape
- ↑ Liu S-P, Lee S-D, Lee H-T, Liu DD, Wang H-J, et al. (2010), "Granulocyte Colony-Stimulating Factor Activating HIF-1α Acts Synergistically with Erythropoietin to Promote Tissue Plasticity", PLoS ONE 5 (4: e10093), DOI:10.1371/journal.pone.0010093